AIGH Capital Management LLC Has $3.55 Million Stock Holdings in PolyPid Ltd. $PYPD

AIGH Capital Management LLC trimmed its holdings in PolyPid Ltd. (NASDAQ:PYPD) by 10.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,065,128 shares of the company’s stock after selling 128,980 shares during the period. PolyPid comprises about 1.0% of AIGH Capital Management LLC’s holdings, making the stock its 25th largest position. AIGH Capital Management LLC owned approximately 6.70% of PolyPid worth $3,552,000 at the end of the most recent quarter.

Separately, Lumbard & Kellner LLC acquired a new stake in shares of PolyPid in the 2nd quarter worth about $135,000. 26.47% of the stock is currently owned by institutional investors and hedge funds.

PolyPid Trading Down 0.6%

Shares of PYPD opened at $4.78 on Friday. The stock has a 50 day moving average of $4.12 and a 200 day moving average of $3.71. The company has a market capitalization of $76.00 million, a price-to-earnings ratio of -1.60 and a beta of 1.51. PolyPid Ltd. has a 12 month low of $2.30 and a 12 month high of $5.05.

PolyPid (NASDAQ:PYPD) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.17. As a group, equities research analysts predict that PolyPid Ltd. will post -1.79 earnings per share for the current year.

Wall Street Analyst Weigh In

PYPD has been the subject of a number of analyst reports. Roth Mkm cut their price target on PolyPid from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Thursday, November 13th. Citigroup reaffirmed a “market outperform” rating on shares of PolyPid in a research report on Monday, December 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of PolyPid in a report on Monday, December 29th. Finally, Wall Street Zen upgraded PolyPid from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $12.40.

PolyPid Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.